Back to top
more

DexCom (DXCM)

(Delayed Data from NSDQ)

$69.00 USD

69.00
3,405,133

-0.70 (-1.00%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $68.91 -0.09 (-0.13%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Instruments

Zacks News

Quest Diagnostics (DGX) & CDC to Assess Hepatitis C Burden

Quest Diagnostics (DGX) and CDC expand research collaboration to better understand the Hepatitis C burden in the United States.

Here's Why You Should Retain Boston Scientific (BSX) Now

Investors are optimistic about Boston Scientific (BSX) on strong worldwide demand for its GI and pulmonary treatment options and traction in Europe for its next-generation WATCHMAN FLX.

Here's Why You Should Retain OPKO Health (OPK) Stock for Now

OPKO Health's (OPK) potential in Rayaldee raises optimism about the stock.

Veeva Systems (VEEV) Beats on Q3 Earnings, Revises FY24 Outlook

Veeva Systems' (VEEV) fiscal Q3 results reflect impressive performances by both segments.

Globus Medical (GMED) Gains From NuVasive Deal, Macro Woes Stay

Globus Medical (GMED) witnesses notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.

OrthoPediatrics (KIDS) Introduces Unit for Non-Surgical Bracing

OrthoPediatrics (KIDS) continues to diversify its non-surgical offerings with the introduction of the DF2 Brace.

Here's Why You Should Retain National Vision (EYE) Stock Now

Investors are optimistic about National Vision's (EYE) stock, banking on comparable store sales growth and a favorable liquidity structure.

Tandem Diabetes (TNDM) Launches Dexcom G7 Integrated t:slim X2

Tandem Diabetes' (TNDM) t:slim X2 is the first AID system in the world to feature Dexcom's most advanced CGM technology.

Is DexCom (DXCM) a Solid Growth Stock? 3 Reasons to Think "Yes"

DexCom (DXCM) possesses solid growth attributes, which could help it handily outperform the market.

3 Reasons to Retain AMN Healthcare (AMN) Stock in Your Portfolio

Investors remain optimistic about AMN Healthcare's (AMN) broad array of services.

Omnicell's (OMCL) Global Expansion Strong, Macro Issues Ail

Omnicell (OMCL) accelerates a shift to cloud-based solutions and tech-enabled services through the launches of Inventory Optimization Service and Central Pharmacy Dispensing Services.

HealthEquity (HQY) Q3 Earnings Surpass Estimates, Margins Up

HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in the majority of its segments, in the third quarter of fiscal 2024.

Neogen (NEOG) to Offer Biosecurity Products With New Pact

Neogen will be able to highlight its biosecurity and horse health products, like the COMPANION range of cleansers and disinfection solutions, through the latest collaboration.

Here's Why You Should Retain Align Technology (ALGN) Stock Now

Investors are optimistic about Align Technology (ALGN) on global expansion and strategic alliance.

West Pharmaceutical's (WST) New Launch to Expand Portfolio

West Pharmaceutical's (WST) latest addition to its portfolio is likely to address the critical need for more drug preparation and delivery options at the point of care.

Why You Should Retain UnitedHealth Group (UNH) Stock Now

Growing membership, expanding government business, strategic acquisitions, improving operating margin and solid growth outlook poise UnitedHealth Group (UNH) well for growth.

Integra Gains From New Product Launches, Mounting Costs Ail

Integra expands the international reach of the CUSA platform and registers DuraGen, DuraSeal, Mayfield and Duo LED lighting in the EMEA and Latin America.

Boston Scientific (BSX) Gains From Global Expansion, FX Woe Ails

Boston Scientific's (BSX) Endoscopy business within MedSurg benefits from strong worldwide demand for its broad range of GI and pulmonary treatment options.

Henry Schein's (HSIC) Zahn Dental and Myerson Enter New Deal

Henry Schein's (HSIC) dental laboratory business, Zahn Dental, is set to exclusively distribute Myerson's New Trusana 3D Premium Denture System.

Here's Why You Should Retain Charles River (CRL) Stock Now

Charles River's (CRL) share price is likely to grow, backed by the strength of the DSA segment.

Community Health (CYH) Sells Three Florida Facilities for $294M

Community Health (CYH) divests three hospitals in Florida to Tampa General Hospital, substantiating its endeavor to intensify its focus on high-growth business areas.

Exact Sciences (EXAS) Up 35.4% YTD: Will the Rally Continue?

Investors are optimistic about Exact Sciences (EXAS), driven by growth in Screening and Precision Oncology segments.

Thermo Fisher (TMO) Advances Health Equity via New Partnership

Thermo Fisher (TMO) announces a collaboration with Project HOPE to improve health outcomes by enabling expanded access to HIV testing and support services in Nigeria.

BiomX (PHGE) Reports Positive Pulmonary Infection Treatment Data

BiomX's (PHGE) BX004 showcases an impressive 14% conversion to a negative P. aeruginosa sputum culture at the end of treatment.

Nevro (NVRO) Up 15.7% Since Last Earnings Report: Can It Continue?

Nevro (NVRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.